BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11916548)

  • 1. Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
    Taïeb J; Artru P; Baujat B; Mabro M; Carola E; Maindrault F; Tournigand C; Krulik M; Louvet C; de Gramont A
    Eur J Cancer; 2002 Mar; 38(5):661-6. PubMed ID: 11916548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
    Taïeb J; Mitry E; Boige V; Artru P; Ezenfis J; Lecomte T; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Ann Oncol; 2002 Aug; 13(8):1192-6. PubMed ID: 12181241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
    Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
    Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
    Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
    Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters JS; Hill ME; Norman AR
    Ann Oncol; 2004 Jan; 15(1):64-9. PubMed ID: 14679122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
    Bazarbashi S; Rahal M; Raja MA; El Weshi A; Pai C; Ezzat A; Ajarim D; Memon M; Al Fadda M
    Chemotherapy; 2002 Sep; 48(4):211-6. PubMed ID: 12218269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
    Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
    Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer.
    Choi IK; Seo HY; Sung HJ; Park KH; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Med Oncol; 2007; 24(1):33-7. PubMed ID: 17673809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
    Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
    Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus.
    Polee MB; Kok TC; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
    Anticancer Drugs; 2001 Jul; 12(6):513-7. PubMed ID: 11459997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.